{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T21:51:32Z","timestamp":1692741092054},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1053\/j.seminoncol.2012.11.002","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T20:17:58Z","timestamp":1360009078000},"page":"45-55","source":"Crossref","is-referenced-by-count":6,"title":["Practical Guide to Supportive Care of Patients With Functional Neuroendocrine Tumors"],"prefix":"10.1053","volume":"40","author":[{"given":"Lowell B.","family":"Anthony","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2012.11.002_bib1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0006-291X(75)80208-7","article-title":"D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule","volume":"65","author":"Rivier","year":"1975","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM198511073131916","article-title":"Rapid reversal of carcinoid crisis with a somatostatin analogue","volume":"313","author":"Kvols","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(86)90584-X","article-title":"Metastatic carcinoid tumors and the carcinoid syndrome","volume":"81","author":"Kvols","year":"1986","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"94","author":"Shojamanesh","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib7","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM198512193132504","article-title":"Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995","volume":"313","author":"Lamberts","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","article-title":"The role of somatostatin and its analogs in the diagnosis and treatment of tumors","volume":"12","author":"Lamberts","year":"1991","journal-title":"Endocr Rev"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1056\/NEJM199011013231805","article-title":"Somatostatin-receptor imaging in the localization of endocrine tumors","volume":"323","author":"Lamberts","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1536-1632(03)00038-6","article-title":"Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT","volume":"5","author":"Kowalski","year":"2003","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0167-0115(82)90144-6","article-title":"Multiple subcutaneous injections of somatostatin induce tachyphylaxis of the suppression of plasma insulin, but not glucagon, in the rat","volume":"4","author":"Marki","year":"1982","journal-title":"Regul Pept"},{"issue":"Suppl 3","key":"10.1053\/j.seminoncol.2012.11.002_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000201195","article-title":"Historical background and natural history of carcinoids","volume":"55","author":"Creutzfeldt","year":"1994","journal-title":"Digestion"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib18","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1007\/BF01536042","article-title":"Use of somatostatin analog in management of carcinoid syndrome","volume":"34","author":"Vinik","year":"1989","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(86)90583-8","article-title":"Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors","volume":"81","author":"Feldman","year":"1986","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM197811092991908","article-title":"The carcinoid flush","volume":"299","author":"Frolich","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004836-200301000-00031","article-title":"Carcinoid crisis induced by external manipulation of liver metastasis","volume":"36","author":"Kharrat","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib22","first-page":"26","article-title":"Carcinoid crisis during a partial hepatic resection; lack of essential drugs: a cause for concern in the tropics","volume":"17","author":"Muralidhar","year":"1996","journal-title":"Trop Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/crad.1999.0167","article-title":"Carcinoid crisis provoked by mammographic compression of metastatic carcinoid tumour of the breast","volume":"56","author":"Ozgen","year":"2001","journal-title":"Clin Radiol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib24","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/bja\/aen237","article-title":"Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist","volume":"101","author":"Castillo","year":"2008","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.sla.0000164073.08093.5d","article-title":"Surgical treatment of advanced-stage carcinoid tumors: lessons learned","author":"Boudreaux","year":"2005","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/mpo.2950060111","article-title":"Management of carcinoid syndrome","volume":"6","author":"Bonomi","year":"1979","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03010865","article-title":"Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome","volume":"35","author":"Parris","year":"1988","journal-title":"Can J Anaesth"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004311-199703540-00009","article-title":"Anesthesia for patients with carcinoid syndrome","volume":"35","author":"Vaughan","year":"1997","journal-title":"Int Anesthesiol Clin"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/02841869309083915","article-title":"Somatostatin analogue phase I trials in neuroendocrine neoplasms","volume":"32","author":"Anthony","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib30","doi-asserted-by":"crossref","first-page":"CR537","DOI":"10.12659\/MSM.881977","article-title":"Predictors of cardiac hepatopathy in patients with right heart failure","volume":"17","author":"Megalla","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib31","first-page":"1295","article-title":"Steroids as pain relief adjuvants","volume":"56","author":"Vyvey","year":"2010","journal-title":"Canadian family physician Medecin de famille canadien"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","article-title":"Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period","volume":"40","author":"Anthony","year":"2011","journal-title":"Pancreas"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM197107292850501","article-title":"Results of treatment in 108 patients with Cushing's syndrome","volume":"285","author":"Orth","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJM199503233321207","article-title":"Cushing's syndrome","volume":"332","author":"Orth","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00024677-200201020-00002","article-title":"Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy","volume":"1","author":"Beauregard","year":"2002","journal-title":"Treat Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1210\/jc.85.1.42","article-title":"Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin","volume":"85","author":"Sarlis","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib37","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/jcem-68-5-988","article-title":"Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide","volume":"68","author":"Bertagna","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib38","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1210\/jcem-67-5-1080","article-title":"Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma","volume":"67","author":"Lamberts","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib39","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1210\/jc.2004-2527","article-title":"Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health","volume":"90","author":"Ilias","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib40","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1002\/cncr.26029","article-title":"Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience","volume":"117","author":"Ejaz","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib41","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib42","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib43","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/jc.2009-1317","article-title":"Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center","volume":"95","author":"Donadille","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486","volume":"61","author":"Nieman","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2011-1264","article-title":"Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion","volume":"97","author":"de Bruin","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.002_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000314224","article-title":"Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone","volume":"92","author":"Castinetti","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0026-0495(96)90107-9","article-title":"Somatostatin analogs in ectopic corticotropin production","volume":"45","author":"von Werder","year":"1996","journal-title":"Metabolism"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib49","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJM200506093522322","article-title":"Cabergoline plus lanreotide for ectopic Cushing's syndrome","volume":"352","author":"Pivonello","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib50","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib51","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/jc.2011-1661","article-title":"Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study","volume":"96","author":"Stuijver","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib52","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","article-title":"Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors","volume":"8","author":"van Zaane","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2265.1995.tb01865.x","article-title":"Pseudo-tumours of the thymus after correction of hypercortisolism in patients with ectopic ACTH syndrome: a report of five cases","volume":"42","author":"Tabarin","year":"1995","journal-title":"Clin Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib54","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","article-title":"Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study","volume":"58","author":"Di Somma","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib55","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.dld.2010.11.007","article-title":"Zollinger-Ellison syndrome: presentation, response to therapy, and outcome","volume":"43","author":"Wilcox","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.mcg.0000159221.77913.ac","article-title":"A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival","volume":"39","author":"Quatrini","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1200\/JCO.1999.17.2.615","article-title":"Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome","volume":"17","author":"Yu","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib59","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01655106","article-title":"Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome","volume":"17","author":"Metz","year":"1993","journal-title":"World J Surg"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib60","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0016-5085(00)70139-9","article-title":"Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome","volume":"118","author":"Lew","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib61","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0016-5085(89)91485-6","article-title":"Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study","volume":"97","author":"Maton","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib62","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/0016-5085(92)91170-9","article-title":"Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high","volume":"103","author":"Metz","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib63","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1365-2036.2008.03658.x","article-title":"Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors","volume":"27","author":"Hirschowitz","year":"2008","journal-title":"Alimentary Pharmacol Therapeut"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2036.1998.00274.x","article-title":"Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy","volume":"12","author":"Stewart","year":"1998","journal-title":"Alimentary Pharmacol Therapeut"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib65","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1210\/jc.2007-2279","article-title":"A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors","volume":"93","author":"Berna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPA.0b013e318243a0b6","article-title":"A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans","volume":"41","author":"Raines","year":"2012","journal-title":"Pancreas"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib67","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00535-002-1170-8","article-title":"Octreotide in control of multiple liver metastases from gastrinoma","volume":"38","author":"Saijo","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib68","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(86)90139-X","article-title":"Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995","volume":"2","author":"Shepherd","year":"1986","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib69","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ijrobp.2008.12.044","article-title":"Radiotherapy for pancreatic neuroendocrine tumors","volume":"75","author":"Contessa","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000102969","article-title":"Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy","volume":"85","author":"Strosberg","year":"2007","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib71","first-page":"73","article-title":"Radiotherapy for unresectable endocrine pancreatic carcinomas","volume":"18","author":"Tennvall","year":"1992","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib72","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib73","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2011.37.2151","article-title":"Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers","volume":"30","author":"Villard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib74","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/cncr.25646","article-title":"Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas","volume":"117","author":"Grozinsky-Glasberg","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib75","first-page":"347","article-title":"Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues","volume":"14","author":"Bodei","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib76","first-page":"125","article-title":"Report from the 1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRRNT), Bad Berka (Germany), June 23-26, 2011","volume":"14","author":"Jurgilewicz","year":"2011","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib77","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1210\/jc.2008-2031","article-title":"Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007","volume":"94","author":"Placzkowski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib78","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncr.21179","article-title":"Malignant insulinoma: spectrum of unusual clinical features","volume":"104","author":"Hirshberg","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib79","first-page":"417","article-title":"Insulinoma: clinical and diagnostic features of 60 consecutive cases","volume":"51","author":"Service","year":"1976","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib80","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2796.1998.00281.x","article-title":"Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1","volume":"243","author":"Jensen","year":"1998","journal-title":"J Intern Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib81","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/pgmj.73.864.640","article-title":"Diazoxide treatment for insulinoma: a national UK survey","volume":"73","author":"Gill","year":"1997","journal-title":"Postgrad Med J"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib82","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/BF01655532","article-title":"Diazoxide in the management of patients with insulinoma","volume":"10","author":"Goode","year":"1986","journal-title":"World J Surg"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib83","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","article-title":"Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours","volume":"37","author":"Aparicio","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib84","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000091408","article-title":"Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2","volume":"65","author":"Romeo","year":"2006","journal-title":"Horm Res"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib85","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","author":"Kulke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib86","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MAJ.0b013e3181ee7be2","article-title":"Management of intractable hypoglycemia with yttirum-90 radioembolization in a patient with malignant insulinoma","volume":"340","author":"Chandra","year":"2010","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2265.2011.04145.x","article-title":"New therapeutic options for metastatic malignant insulinomas","volume":"75","author":"de Herder","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib88","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2011-1563","article-title":"Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy","volume":"96","author":"van Schaik","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib89","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1067\/msy.1998.92005","article-title":"Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature","volume":"124","author":"Smith","year":"1998","journal-title":"Surgery"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib90","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.80.8.2273","article-title":"Clinical review 72: diagnosis and management of functioning islet cell tumors","volume":"80","author":"Perry","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib91","first-page":"282","article-title":"VIPoma syndrome","volume":"14","author":"Mekhjian","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(87)90425-6","article-title":"VIPoma syndrome","volume":"82","author":"Krejs","year":"1987","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0016-5085(85)80153-0","article-title":"Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases","volume":"88","author":"Kraenzlin","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib94","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1148\/rg.284075170","article-title":"Neuroendocrine tumors: role of interventional radiology in therapy","volume":"28","author":"Steward","year":"2008","journal-title":"Radiographics"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib95","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000090257","article-title":"Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma","volume":"6","author":"Moug","year":"2006","journal-title":"Pancreatology"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib96","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJM196606232742503","article-title":"A glucagon-secreting alpha-cell carcinoma of the pancreas","volume":"274","author":"McGavran","year":"1966","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib97","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00000441-200105000-00003","article-title":"The glucagonoma syndrome: a review of its features and discussion of new perspectives","volume":"321","author":"Chastain","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00005792-199603000-00002","article-title":"The glucagonoma syndrome","volume":"75","author":"Wermers","year":"1996","journal-title":"Medicine"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib99","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1210\/edrv-2-3-347","article-title":"The glucagonoma syndrome: clinical features, diagnosis, and treatment","volume":"2","author":"Stacpoole","year":"1981","journal-title":"Endocr Rev"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00000441-199506000-00006","article-title":"Case report: diabetic ketoacidosis in a patient with glucagonoma","volume":"309","author":"Anthony","year":"1995","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib101","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJM198606263142606","article-title":"Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995","volume":"314","author":"Boden","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib102","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000199835","article-title":"Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature","volume":"42","author":"Rosenbaum","year":"1989","journal-title":"Digestion"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7326\/0003-4819-91-2-213","article-title":"Amino acid deficiency and the skin rash associated with glucagonoma","volume":"91","author":"Norton","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib104","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/02841869109092411","article-title":"The role of interferons in the management of carcinoid tumors","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib105","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1056\/NEJM197704282961703","article-title":"\u201cSomatostatinoma\u201d: a somatostatin-containing tumor of the endocrine pancreas","volume":"296","author":"Ganda","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib106","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0140-6736(77)92113-4","article-title":"Pancreatic somatostatinoma","volume":"1","author":"Larsson","year":"1977","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib107","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/gut.42.6.792","article-title":"Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours","volume":"42","author":"Angeletti","year":"1998","journal-title":"Gut"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib108","first-page":"13","article-title":"Somatostatinoma\/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas","volume":"18","author":"Soga","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.002_bib109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000051856","article-title":"Natural history of neuroendocrine enteropancreatic tumors","volume":"62","author":"Mignon","year":"2000","journal-title":"Digestion"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jso.20957","article-title":"Management of hepatic metastasis of gastrointestinal carcinoid tumors","volume":"97","author":"Landry","year":"2008","journal-title":"J Surg Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib111","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib112","first-page":"317","article-title":"Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors","volume":"53","author":"Van De Wiele","year":"2009","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib113","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/PPO.0b013e3181d7e8cf","article-title":"Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies","volume":"16","author":"Kennedy","year":"2010","journal-title":"Cancer J"},{"key":"10.1053\/j.seminoncol.2012.11.002_bib114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jvir.2007.09.006","article-title":"Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization","volume":"19","author":"Murthy","year":"2008","journal-title":"J Vasc Interv Radiol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T20:52:47Z","timestamp":1539895967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775412002011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0093775412002011"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}